Oral Insulin Begins Marketing in India

Generex Biotechnology Corporation announces it will begin marketing their Oral-lyn Insulin, which gets absorbed through the inner lining of the mouth. The first effort in this marketing launch campaign involves presentations about Generex Oral-lyn to Indian key opinion leaders and endocrinologists in India at closed-door meetings in Mumbai, India.

The presentations focus on all drug handling matters concerning Generex Oral-lyn for Type 1, Type 2, and IGT (Impaired Glucose Tolerance) populations. Generex Oral-lyn is a prandial (mealtime) insulin and provides safe and effective glucose control for up to 2 hours after each meal. Generex Oral-lyn is a convenient and pain-free alternative to insulin injections and could encourage prandial insulin therapy among those patients who presently avoid injections. Missed injections for patients with Type 1 diabetes mellitus can eventually lead to health complications including heart condition, stroke, blindness, amputation, and kidney failure, to name a few.

Generex Oral-lyn is a prandial insulin which allows for easy self-administration, precise dosage control, and easy titration which allows for finer individual control. As such, Generex Oral-lyn also makes an ideal supplement at meal times for patients with Type 2 diabetes mellitus in addition to basal or combination therapies based on blood glucose measurements.
India has a significant and growing number of people with diabetes. According to the Diabetes Atlas 2007, there are approximately 40.8 million diagnosed patients with diabetes in India. There are also an estimated 35.9 million people who have pre-diabetic conditions which, if not properly treated and managed, could lead to full-blown diabetes. Generex believes that early intervention with insulin therapy could delay the onset and progression of diabetes and its numerous complications.

"We are very excited about the marketing launch activities taking place in India by Shreya, the fifth largest distributor of insulin in the Indian insulin market" said Anna Gluskin, Generex’s President and Chief Executive Officer. "This demonstrates Shreya’s commitment to entering this major jurisdiction with the proper educational tools for its marketing purposes and for training amongst physicians who will be the front runners in educating patients living with diabetes. We look forward to having both teams work closely to facilitate a successful product launch in India and to follow up with continuous educational programs throughout the course of the year."

The Company’s flagship product, oral insulin (Generex Oral-lyn), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. 

================================

FACT:
Link Between Vitamin E and Decline in Physical Function: Low serum concentration of vitamin E, an indication of poor nutrition, is associated with physical decline for older persons.Researchers at Yale University School of Medicine collected data in a randomly selected group of Italian men and women age 65 and older.  They compared nutrient levels in blood with the ability to perform basic skills such as walking, standing up from a chair and balancing.  Out of nearly seven hundred people studied, about half experienced a decline in physical function within three years.  The study found low levels of vitamin E were associated with the decline.  See this weeks’ Item #7